8.1 Cytotoxic drugs

File Publication type No. Publishedsort ascending
Ruxolitinib for myelofibrosis Evaluation Reports - Jan 13
Belimumab for the treatment of Systemic Lupus Erythematosus (SLE) Evaluation Reports - Apr 12
Sunitinib for the treatment of Pancreatic Neuroendocrine Tumours (PNETs) Evaluation Reports - Mar 11
Abiraterone for the treatment of castration-resistant prostate cancer Evaluation Reports - Feb 11
Bendamustine for rituximab-refractory non-hodgkin’s lymphoma Evaluation Reports - Feb 11
Cabazitaxel for the treatment of metastatic hormone-refractory prostate cancer Evaluation Reports - Feb 11
Sorafenib for the treatment of locally advanced or metastatic medullary thyroid cancer Evaluation Reports - Feb 11
Vandetanib in locally advanced or metastatic medullary thyroid cancer Evaluation Reports - Feb 11
Nanoparticle albumin-bound paclitaxel in the management of metastatic breast cancer Evaluation Reports - May 10
Panitumumab in the management of metastatic colorectal cancer (N) Evaluation Reports - Jun 09
Azacitidine for the management of myelodysplastic syndromes (N) Evaluation Reports - May 09
Ibritumomab as consolidation therapy after remission induction in previously untreated follicular lymphoma Evaluation Reports - May 09
Lapatinib in the management of metastatic breast cancer Evaluation Reports - Nov 08
Myocet in the management of metastatic breast cancer Evaluation Reports - Oct 08
Dasatinib in the management of acute lymphoblastic leukaemia in adults Evaluation Reports - Aug 08
Dasatinib in the management of acute lymphoblastic leukaemia in adults Evaluation Reports - Aug 08